Close Menu

NEW YORK – Canaccord Genuity today initiated coverage of skin cancer test developer Castle Biosciences, with a Buy rating and a price target of $26 per share.

SVB Leerink also initiated coverage of the firm with an Outperform rating and provided a price target of $28 per share. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.